Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576483 | 0.98 | CA12 (0.44) | CA12CA1CA9MAOBCYP1A2 | |
| SCHEMBL9293197 | 0.90 | GABRG2 (0.43) | CA12CA1CA9CYP1A2GAA | |
| SCHEMBL7706827 | 0.88 | CA1 (0.50) | CA12CA1CA9CYP1A2GAA | |
| SCHEMBL6158612 | 0.85 | HSP90AA1 (0.50) | CA12CA1CA9MAOBHSP90AA1 | |
| SCHEMBL9718082 | 0.84 | MAOB (0.37) | CA12CA1CA9MAOBCYP1A2 | |
| SCHEMBL4576012 | 0.83 | CA12 (0.37) | CA12CA1CA9MAOBCYP1A2 | |
| SCHEMBL18529823 | 0.83 | MAOB (0.43) | CA12CA1CA9MAOBCYP1A2 | |
| SCHEMBL8076860 | 0.83 | CA12 (0.37) | CA12CA1CA9CYP1A2GAA | |
| SCHEMBL3182564 | 0.82 | CA12 (0.46) | CA12CA1CA9MAOBGAA | |
| SCHEMBL3428405 | 0.82 | MAOB (0.46) | MAOBCYP1A2GAAMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041153-B | Direct cross coupling method of aryl thioether and aryl bromine | 南京工业大学 | 2024-05-24 | — | — | CN | claimed |
| CN-116253623-B | Direct cross-coupling method of aryl fluorine sulfate and aryl bromine | 南京工业大学 | 2024-04-05 | — | — | CN | claimed |
| CN-116554009-A | Electrophilic cross-coupling reaction method of aryl sulfone or heteroaryl sulfone and aryl bromide | 南京工业大学 | 2023-08-08 | — | — | CN | claimed |
| CN-116283515-A | Direct cross coupling method of aryl fluoride and aryl bromide | 南京工业大学 | 2023-06-23 | — | — | CN | claimed |
| CN-116253623-A | Direct cross-coupling method of aryl fluorine sulfate and aryl bromine | 南京工业大学 | 2023-06-13 | — | — | CN | claimed |
| CN-116041153-A | Direct cross coupling method of aryl thioether and aryl bromine | 南京工业大学 | 2023-05-02 | — | — | CN | claimed |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2019-01-10 | — | — | US | claimed |
| WO-2017030983-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | WO | claimed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| CN-115916763-B | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995004051-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-4195178-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4181798-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | CA12 2835/4885CA1 3007/4885CA9 2433/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | CA12 2835/4885CA1 3007/4885CA9 2433/4885 |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, MAVS | CA12 3710/4885CA1 4762/4885CA9 2522/4885 |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSS, CTSB, CTSK | CA12 2529/4885CA1 1252/4885CA9 1557/4885 |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, MAVS | CA12 3710/4885CA1 4762/4885CA9 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.